Skip to main content
Fig. 6 | Cell Communication and Signaling

Fig. 6

From: Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency

Fig. 6

ARID1A expression serves as a novel biomarker for resistance to first-generation EGFR-TKIs in EGFR-mutant lung adenocarcinoma patients. A Underlying mechanisms based on differentially expressed proteins revealed by mass spectrometry for phosphorylated proteins, which might be associated with resistance to EGFR-TKIs. B Representative images of IHC staining of ARID1A in EGFR-mutant lung adenocarcinoma. C Progression-free survival after treatment with first-generation EGFR-TKIs in all enrolled patients and patients who received gefitinib (divided by ARID1A expression). D ROC curve for ARID1A expression in predicting the progression-free survival of patients treated with first-generation EGFR-TKIs. E The construction and verification of a nomogram based on ARID1A expression and ECOG score for EGFR-mutant lung adenocarcinoma patients who received first-generation EGFR-TKIs. F Drug selection based on the NCI-60 database for non-small cell lung cancer patients with ARID1A deficiency

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X